Christophe Tournerie, MD – Owner and CEO Clinical research activity in Asia is already very strong mainly due to large pharma companies who have already included Asia in their scope for at least 10 years. These global pharma companies also prefer vendor agreements with global CROs that have a strong presence in Asia. CROs with deep investigator pools and a cultural understanding in a region becomes vital to a clinical trial’s success.      

Medium size pharma as well as biotech companies may not yet have included Asia in their clinical trials although the opportunity exists for them as well. This can be attributed to either lack of awareness of capabilities that exist in Asia or not having found the right CRO partner with Asian capabilities and a size that is adapted to these companies’ needs.  

Now is the time for these companies to consider Asia due to its large treatment naïve patient population, international quality standards, and accelerated timelines for patient enrollment. The key to including Asia in their clinical trial footprint is sponsors to partner with specific Asian based CROs with capabilities and a cultural understanding to provide a flexible and cost effective approach to regional clinical trials.

ClinActis Pte Ltd - 112 Robinson Road - #06-04 - Singapore 068902 Telephone: +65 6436 5500 - info@clinactis.com

The Time is Now for Clinical Trials in Asia